Immunogenicity and safety of the fourth dose of quadrivalent human papillomavirus (HPV) vaccine in immunosuppressed women who did not seroconvert after three doses
Although safe, the fourth 4vHPV vaccine dose led to seroconversion in only few immunosuppressed women who had not seroconverted after three doses.
Authors
- Vanessa Infante (ORCID: https://orcid.org/0000-0002-1812-5122)
- Philippe Mayaud (ORCID: https://orcid.org/0000-0001-5730-947X)
- Karina Takesaki Miyaji (ORCID: https://orcid.org/0000-0003-2653-3975)
- Joakim Dillner (ORCID: https://orcid.org/0000-0001-8588-6506)
- Hanna Kann (ORCID: https://orcid.org/0000-0003-2014-5437)
- Ana Marli Christovam Sartori (ORCID: https://orcid.org/0000-0003-3777-0757)
- Camila Cristina Martini Rodrigues (ORCID: https://orcid.org/0000-0001-5340-5886)
- Carina Eklund
- Amanda Nazareth Lara (ORCID: https://orcid.org/0000-0002-4294-0282)
- Lívia Zignago Moreira dos Santos
- Camila de Melo Picone (ORCID: https://orcid.org/0000-0002-2455-5831)
Institutions
- Karolinska Institutet (SE)
- London School of Hygiene & Tropical Medicine (GB)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
Publication Details
- Journal
- Frontiers in Cellular and Infection Microbiology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.3389/fcimb.2024.1451308
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo